Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.30 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3088181 | 0.77 | MVD (0.41) | KDM4ETSHRTET2 | |
| SCHEMBL19169705 | 0.77 | ALDH1A1 (0.33) | — | |
| SCHEMBL19176892 | 0.76 | OPRM1 (0.31) | — | |
| SCHEMBL19169693 | 0.75 | — | — | |
| SCHEMBL8990009 | 0.75 | CA12 (0.42) | KDM4EHTTMEN1KMT2ACA12 | |
| SCHEMBL23135884 | 0.75 | MEN1 (0.39) | KDM4EHTTMEN1KMT2ACA12 | |
| SCHEMBL19821450 | 0.75 | ALDH1A1 (0.43) | KDM4EHTTMEN1KMT2ACA12 | |
| SCHEMBL14902242 | 0.75 | MGAM (0.52) | KDM4EHTTMEN1KMT2ACA12 | |
| SCHEMBL10266347 | 0.75 | MEN1 (0.39) | KDM4EHTTMEN1KMT2ACA12 | |
| SCHEMBL21070174 | 0.74 | KDM4E (0.37) | KDM4EHTTMEN1KMT2ACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795255-B2 | Rigidified compounds for modulating heparanase activity | INSIGHT BIOPHARMACEUTICALS LTD. (IL) | 2010-09-14 | — | — | US | claimed |
| US-11753369-B2 | Creatine prodrugs, compositions and methods of use thereof | ULTRAGENYX PHARMACEUTICAL INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-7795255-B2 | Rigidified compounds for modulating heparanase activity | INSIGHT BIOPHARMACEUTICALS LTD. (IL) | 2010-09-14 | — | — | US | disclosed |
| US-20080039456-A1 | Rigidified Compounds for Modulating Heparanase Activity | INSIGHT BIOPHARMACEUTICALS LTD. (IL) | 2008-02-14 | — | — | US | disclosed |
| EP-1846383-A2 | RIGIDIFIED COMPOUNDS FOR MODULATING HEPARANASE ACTIVITY | Insight Biopharmaceuticals Ltd. (IL) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006072953-A2 | RIGIDIFIED COMPOUNDS FOR MODULATING HEPARANASE ACTIVITY | INSIGHT BIOPHARMACEUTICALS LTD. (IL) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11753369-B2 | Creatine prodrugs, compositions and methods of use thereof | CKMT1A; CKMT1B, PYGM, TKT | KDM4E 1255/4885HTT 4330/4885MEN1 4024/4885 |
| US-20080039456-A1 | Rigidified Compounds for Modulating Heparanase Activity | HPSE, HEXA, GAA | KDM4E 2167/4885HTT 56/4885MEN1 3219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.